$VCEL
Vericel Corp Stock $vcel

$vcel Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000110465913083613 Filed on November 12, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$10.00K	$0.00	$0.00
YoY Change	-47.37%		-100.0%
Cost Of Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Gross Profit	$10.00K	$0.00	$0.00
YoY Change	-50.0%		-100.0%
Gross Profit Margin	100.0%
Selling, General & Admin	$1.620M	$1.066M	$2.138M
YoY Change	0.0%	-50.14%	26.06%
% of Gross Profit	16200.0%
Research & Development	$3.320M	$2.575M	$6.147M
YoY Change	-44.76%	-58.11%	6.9%
% of Gross Profit	33200.0%
Depreciation & Amortization	$100.0K	$110.0K	$150.0K
YoY Change	-37.5%	-26.67%	-6.25%
% of Gross Profit	1000.0%
Operating Expenses	$4.930M	$3.641M	$8.285M
YoY Change	-35.47%	-56.05%	11.27%
Operating Profit	-$4.920M	-$3.641M	-$8.285M
YoY Change	-35.41%	-56.05%	11.37%
Interest Expense	$2.010M	$3.000K	$4.000K
YoY Change	107.22%	-25.0%	33.33%
% of Operating Profit
Other Income/Expense, Net		$1.368M	$2.251M
YoY Change		-39.23%	-59.11%
Pretax Income	-$2.920M	-$2.270M	-$6.030M
YoY Change	-56.09%	-62.35%	212.44%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$2.920M	-$2.273M	-$6.034M
YoY Change	-56.09%	-62.33%	212.0%
Net Earnings / Revenue	-29200.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$650.3K	-$746.7K	-$2.779M
COMMON SHARES
Basic Shares Outstanding	4.380M shares		42.59M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.100M	$10.80M	$21.10M
YoY Change	-40.44%	-48.82%	77.31%
Cash & Equivalents	$8.059M	$10.82M	$21.09M
Short-Term Investments
Other Short-Term Assets	$409.0K	$545.0K	$364.0K
YoY Change	16.19%	49.73%	-41.48%
Inventory	$0.00
Prepaid Expenses
Receivables	$8.000K		$0.00
Other Receivables	$0.00		$0.00
Total Short-Term Assets	$8.476M	$11.36M	$21.50M
YoY Change	-39.41%	-47.16%	70.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$739.0K	$841.0K	$1.246M
YoY Change	-37.79%	-32.5%	-16.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$739.0K	$841.0K	$1.208M
YoY Change	-37.79%	-30.38%	-19.14%
TOTAL ASSETS
Total Short-Term Assets	$8.476M	$11.36M	$21.50M
Total Long-Term Assets	$739.0K	$841.0K	$1.208M
Total Assets	$9.215M	$12.20M	$22.71M
YoY Change	-39.29%	-46.27%	61.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.355M	$2.900M	$3.200M
YoY Change	-17.16%	-9.38%	33.33%
Accrued Expenses	$294.0K	$300.0K	$700.0K
YoY Change	-27.23%	-57.14%	-30.0%
Deferred Revenue
YoY Change
Short-Term Debt	$6.000K	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.000K	$10.00K	$40.00K
YoY Change	-82.35%	-75.0%	-21.57%
Total Short-Term Liabilities	$5.321M	$7.252M	$7.000M
YoY Change	-5.97%	3.6%	-72.2%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$9.000K
YoY Change	-100.0%	-100.0%	-81.63%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$9.000K
YoY Change	-100.0%	-100.0%	-81.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.321M	$7.252M	$7.000M
Total Long-Term Liabilities	$0.00	$0.00	$9.000K
Total Liabilities	$5.321M	$7.252M	$6.989M
YoY Change	-6.07%	3.76%	-72.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$287.8M	-$284.8M	-$267.4M
YoY Change	4.52%	6.5%	11.86%
Common Stock	$253.3M	$251.4M	$242.8M
YoY Change	4.13%	3.54%	6.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.894M	$4.950M	-$24.64M
YoY Change
Total Liabilities & Shareholders Equity	$9.215M	$12.20M	$22.71M
YoY Change	-39.29%	-46.27%	61.37%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$2.920M	-$2.273M	-$6.034M
YoY Change	-56.09%	-62.33%	212.0%
Depreciation, Depletion And Amortization	$100.0K	$110.0K	$150.0K
YoY Change	-37.5%	-26.67%	-6.25%
Cash From Operating Activities	-$4.340M	-$4.140M	-$7.660M
YoY Change	-40.87%	-45.95%	24.76%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$80.00K
YoY Change	-100.0%	-100.0%	-79.49%
Acquisitions
YoY Change
Other Investing Activities	$0.00		$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$80.00K
YoY Change	-100.0%	-100.0%	-79.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$8.200M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.580M	10.46M	160.0K
YoY Change	-15900.0%	6437.5%	-500.0%
NET CHANGE
Cash From Operating Activities	-4.340M	-4.140M	-7.660M
Cash From Investing Activities	0.000	0.000	-80.00K
Cash From Financing Activities	1.580M	10.46M	160.0K
Net Change In Cash	-2.760M	6.320M	-7.580M
YoY Change	-62.95%	-183.38%	15.37%
FREE CASH FLOW
Cash From Operating Activities	-$4.340M	-$4.140M	-$7.660M
Capital Expenditures	$0.00	$0.00	-$80.00K
Free Cash Flow	-$4.340M	-$4.140M	-$7.580M
YoY Change	-40.06%	-45.38%	31.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	astm	Maximum Period Before Cash And Cash Equivalents Are Fully Depleted MaximumPeriodBeforeCashAndCashEquivalentsAreFullyDepleted	P1Y
	astm	Minimum Period Of Uncertainty Regarding Entitys Ability To Maintain Liquidity Sufficient To Operate Business Effectively MinimumPeriodOfUncertaintyRegardingEntitysAbilityToMaintainLiquiditySufficientToOperateBusinessEffectively	P12M
CY2012Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10816000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	item
CY2012Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1995000	USD
CY2013Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	4025000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3331000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	29260000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	48671000	shares
CY2013Q1	us-gaap	Restructuring Charges RestructuringCharges	408000	USD
CY2013Q3	us-gaap	Restructuring Reserve RestructuringReserve	83000	USD
	dei	Entity Registrant Name EntityRegistrantName	AASTROM BIOSCIENCES INC
	dei	Entity Central Index Key EntityCentralIndexKey	0000887359
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4380302	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2012Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	41613000	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">2.   Basis of Presentation</font></b></p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 13.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The condensed consolidated financial statements included herein have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC).  Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) have been omitted pursuant to such rules and regulations. The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated.  The results of operations for the nine months ended September 30, 2013, are not necessarily indicative of the results to be expected for the full year or for any other period.  The December 31, 2012 condensed consolidated balance sheet data was derived from audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP.</font></p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 13.5pt; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 13.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the period ended December 31, 2012, as filed with the SEC.</font></p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 13.5pt; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 13.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The consolidated financial statements include the accounts of Aastrom and its wholly-owned subsidiaries, Aastrom Biosciences GmbH, located in Berlin, Germany, Aastrom Biosciences, SL, located in Barcelona, Spain and Marrow Donation, LLC, located in San Diego, California (collectively, the Company).  All inter-company transactions and accounts have been eliminated in consolidation.  The subsidiaries are not a significant component of the consolidated financial statements as each has limited operations historically and Aastrom Biosciences GmbH and Aastrom Biosciences, SL have ceased operations.</font></p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt;"> </p> </div>
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13638000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	352000	USD
CY2013Q3	us-gaap	Other Assets Current OtherAssetsCurrent	545000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	13990000	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	11361000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1188000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	841000	USD
CY2012Q4	us-gaap	Assets Assets	15178000	USD
CY2013Q3	us-gaap	Assets Assets	12202000	USD
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3247000	USD
CY2013Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2918000	USD
CY2012Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	383000	USD
CY2013Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	299000	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	34000	USD
CY2013Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	10000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5659000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7252000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	5665000	USD
CY2013Q3	us-gaap	Liabilities Liabilities	7252000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	243215000	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	251358000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-275315000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-284797000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-32100000	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	4950000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15178000	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12202000	USD
	astm	Net Proceeds From Issuance Or Sale Of Equity NetProceedsFromIssuanceOrSaleOfEquity	3337000	USD
CY2013Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43784000	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43784000	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86443000	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86443000	shares
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	11000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1909000	USD
	astm	Research And Development Agreements ResearchAndDevelopmentAgreements	2105000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	9901000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	2000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	11000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	13915000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3050000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6147000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2575000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20012000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11789000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	228519000	USD
CY2012Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2138000	USD
CY2013Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1066000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6131000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4259000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	96857000	USD
CY2012Q3	us-gaap	Costs And Expenses CostsAndExpenses	8285000	USD
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	3641000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	26145000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	16051000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	328426000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8285000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3641000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26143000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16040000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-314511000	USD
CY2012Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2241000	USD
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43336000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60847000	shares
CY2013Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1367000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3289000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-19868000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1249000	USD
CY2012Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	14000	USD
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	40000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	12000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	10834000	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	4000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	3000	USD
	us-gaap	Interest Expense InterestExpense	10000	USD
	us-gaap	Interest Expense InterestExpense	9000	USD
	us-gaap	Interest Expense InterestExpense	500000	USD
CY2012Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2251000	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1368000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3319000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3334000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	31451000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-6034000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-2273000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22824000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12706000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-283060000	USD
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	2738000	USD
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	1263000	USD
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	6224000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.63
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40331000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50517000	shares
	us-gaap	Inventory Write Down InventoryWriteDown	2240000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	3300000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	487000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	387000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8534000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-110000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	-1704000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3166000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	528000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	18023000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	204000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2335000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-272000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	65000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	646000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	281000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-329000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2686000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-300000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-84000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	299000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-22207000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15600000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-272217000	USD
	astm	Organizational Costs Activity OrganizationalCostsActivity	73000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7530000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	400000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-169000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	217041000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	218745000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	169000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	40000	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3500000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	751000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	31000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	30000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-40000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2870000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-18000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	37935000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12818000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	288532000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	15559000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5499000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	37620000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	89267000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	346000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	12848000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	197902000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-2822000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	10816000	USD
	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	-10382000	USD
	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	-10382000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5530000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21089000	USD
	astm	Class Of Warrant Or Right Warrants Issued Value ClassOfWarrantOrRightWarrantsIssuedValue	5874000	USD
	astm	Class Of Warrant Or Right Warrants Exercised Value ClassOfWarrantOrRightWarrantsExercisedValue	513000	USD
CY2013Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	8169000	USD
CY2012Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1218000	USD
CY2013Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1368000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7252000	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3641000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25562000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16651000	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2738000	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3945000	USD
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26

Files In Submission

Name	View Source	Status
0001104659-13-083613-index-headers.html	Edgar Link	pending
0001104659-13-083613-index.html	Edgar Link	pending
0001104659-13-083613.txt	Edgar Link	pending
0001104659-13-083613-xbrl.zip	Edgar Link	pending
a13-19722_110q.htm	Edgar Link	pending
a13-19722_1ex31d1.htm	Edgar Link	pending
a13-19722_1ex31d2.htm	Edgar Link	pending
a13-19722_1ex32d1.htm	Edgar Link	pending
astm-20130930.xml	Edgar Link	completed
astm-20130930.xsd	Edgar Link	pending
astm-20130930_cal.xml	Edgar Link	unprocessable
astm-20130930_def.xml	Edgar Link	unprocessable
astm-20130930_lab.xml	Edgar Link	unprocessable
astm-20130930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VCEL
Vericel Corp Stock $vcel

2013 Q4 Form 10-Q Financial Statement

#000110465913083613 Filed on November 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL Vericel Corp Stock $vcel

2013 Q4 Form 10-Q Financial Statement

#000110465913083613 Filed on November 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL
Vericel Corp Stock $vcel